VEGFA and gastric cancer: Moreover, when used as a first-line treatment, the combination of bevacizumab, a monoclonal antibody directed against VEGF-A, in combination with chemotherapy has been associated with significantly improved rates of ORR and progression-free survival (PFS) in metastatic GC patients.